Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Ovarian Cancer, Breast Cancer, Colorecta...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Behavioral: Genetic Testing and Counseling — Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
  • Behavioral: Screening Form — Participant will be answering demographic details

Primary Outcomes

  • To identify underserved women at risk for hereditary breast and colorectal cancers eligible for standard-of-care genetic counseling using national screening guidelines. (through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-18
Completion: 2027-02-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: Community Outreach and Engagement Fund for Underserved Texans
Principal Investigators:
  • Arun Banu, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Arun Banu, MD
(713) 792-2817
barun@mdanderson.org
Arun Banu, MD
713-792-2817
barun@mdanderson.org
M D Anderson Cancer Center
Arun Banu, MD
M D Anderson Cancer Center
Interventions
  • Behavioral: Genetic Testing and Counseling — Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
  • Behavioral: Screening Form — Participant will be answering demographic details
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: Any woman scheduled at Project VALET mammography screening mobile units will be eligible for this study. Exclusion Criteria:
Conditions Major Depressive Disorder, Anxiety Depre...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Placebo — (4-week ramp, 4-week steady dosing)
  • Drug: Pregnenolone — (4-week ramp, 4-week steady dosing)

Primary Outcomes

  • Gamma-aminobutyric acid (GABA) Concentration (Day 14, Day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-03
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Institute of Mental Health (NIMH), Institute for Medical Research, Inc.
Principal Investigators:
  • Shibani S. Mukerji, MD, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Hemi Park, MPH
857-282-3788
MGHSOOTHE@PARTNERS.ORG
Shibani S. Mukerji, MD, PhD
857-282-9950
SMUKERJI@MGB.ORG
Shibani Mukerji, MD, PhD
Massachusetts General Hospital
Interventions
  • Drug: Placebo — (4-week ramp, 4-week steady dosing)
  • Drug: Pregnenolone — (4-week ramp, 4-week steady dosing)
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * 18-85 years * HIV-1 viral load \<200 copies/mL on antiretroviral therapy (ART) at screening visit * Center for Epidemiological Studies - Depression (CES-D) score ≥ 20 Exclusion Criteria: * Contraindication to magnetic resonance imaging (MRI) or poor-quality baseline MRI preventing image analyses as determined by radiologist assessment * Recent severe infections including opportunistic infections, active bacterial, mycobacterial, fungal, or certain viral infections * Vulnerable populations (e.g., pregnant/nursing, severe cognitive or intellectual impairment, incarcerated) * Use of cobicistat or ritonavir * High risk for suicide (active suicidal ideation (SI) with plan/intent as assessed by using the Columbia Suicide Severity Rating (C-SSRS) or \> 2 attempts in lifetime or any in the past 6 months) or expresses homicidal ideation necessitating clinical intervention or representing an imminent concern * Any severe (life-threatening or unstable) medical condition as determined by clinician assessment * Blood pressure, with the lowest reading taken after three repeat readings during screening visit, ≥ 160 mmHg systolic OR ≥ 95 mmHg diastolic or other life-threatening vital signs as determined by clinician assessment * Clinically significant abnormalities in physical examination or ECG that would interfere with study participation * Decompensated cirrhosis, active liver inflammation (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≥ 5 times the upper limit of normal) or unsuppressed viral hepatitis B or C infection * Severe renal disease (estimated glomerular filtration rate ≤ 30 mL/min/1.73m2) * Seizure disorder requiring antiepileptic treatment * History of allergic reaction or side effects with prior pregnenolone use * Currently using testosterone enanthate, testosterone cypionate, or estrogen containing preparations that significantly increase systemic estrogen levels, including but not limited to oral and transdermal forms of estrogen. All other forms of exogenous sex steroid hormones will be evaluated at the discretion of the PI and/or clinical delegates. * Currently using systemic immunosuppressive agents, including corticosteroids, chemotherapy, or specific immunomodulating agents, such as monoclonal antibodies and TNF-inhibitors * Excessive alcohol or other substances use that would interfere with classification of major depression disorder, study procedures and/or follow-up * Current diagnosis of bipolar disorder * Diagnosis of a psychotic disorder (current or lifetime) * Diagnosis of schizophrenia (current or lifetime) * \<70% adherence to study drug prior to randomization * Inability to swallow pills/capsules * Not able to complete neuropsychological testing in English * Concurrent participation in another interventional trial, except for lifestyle and device studies (For vaccination studies, individuals in the observation period are not exclusionary. Other interventions will be evaluated at the discretion of the PI and/or clinical delegates.)
Conditions Breast Cancer
Phase NA
Enrollment 2032
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) — In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.

Primary Outcomes

  • Cancer Detection Rate (Year 0)
  • Recall Rate (1 Year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-24
Completion: 2027-07-31
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2032 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: American College of Radiology
Collaborators: GE Healthcare, Breast Cancer Research Foundation
Contact Information
Study Contact:
Christopher Comstock, MD
212-746-6000
chc4050@med.cornell.edu
Etta Pisano, MD
Kathryn Zamora, MD
qmooney@uabmc.edu
University of Alabama, Birmingham
Interventions
  • Diagnostic Test: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) — In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
Study Locations (13 sites)
University of Alabama, Birmingham, Birmingham, Alabama 35233 United States
Boca Raton Regional Hospital - Christine E. Lynn Women's Health and Wellness Institute, Boca Raton, Florida 33486 United States
Lake Medical Imaging, The Villages, Florida 32159 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Boston Breast Diagnostic Center, Wellesley Hills, Massachusetts 02481 United States
Henry Ford Health, Detroit, Michigan 48202 United States
Thomas Jefferson University, Sewell, New Jersey 08080 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Carolina Breast Imaging Specialists, Greenville, North Carolina 27834 United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * 1\. Women must have mammographically dense breasts, ACR BI-RADS® lexicon categories c or d (heterogeneous or extreme fibroglandular tissue) on their most recent prior screening. * 2\. Women agree to not undergo whole breast screening ultrasound for the duration of the trial until the year 2 standard of care imaging. * 3\. Women must not have symptoms or signs of benign or malignant breast disease (e.g., bloody, or clear nipple discharge, breast lump, focal breast pain). * 4\. Women must be able to undergo intravenous (IV) administration of iodinated contrast (e.g., no contraindication to intravenous contrast administration for Omnipaque \[iohexol\], and no known allergy-like reaction to iodine or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology \[ACR\]: https://www.acr.org/-/media/ACR/files/clinical-resources/contrast\_media.pdf). * 5\. Women must not be pregnant or breast-feeding. All females of childbearing potential who are uncertain if they could be pregnant or may be pregnant or as per local site standard of practice in women undergoing DBT and CESM must have a negative blood test or urine pregnancy test prior to Omnipaque (iohexol) administration. A female of childbearing potential is any woman, regardless of sexual orientation, sexual identity or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). * 6\. Women of childbearing potential must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the following year until the Year 1 DBT and CESM studies are performed. Exclusion Criteria: * 1\. Women currently undergoing treatment for breast cancer, or planning surgery for a high-risk lesion (ADH, ALH, LCIS, papilloma, radial scar). * 2\. Women who have had the following are not eligible: 1. a mammogram less than 11 months prior to study entry. 2. screening breast ultrasound within 11 months prior to study entry. 3. breast MRI less than 36 months prior to study entry. 4. contrast-enhanced spectral mammography less than 36 months prior to study entry. 5. molecular breast imaging (MBI) less than 36 months prior to study entry. 6. breast prosthetic implants (silicone or saline). 7. suspected of being at high-risk for breast cancer, as defined by the ACS breast MR screening recommendations (lifetime risk of ≥20%-25%) unless they are unable to undergo an MRI. (Reference Appendix I) 8. a history of sickle cell disease. * 3\. Women with known or suspected renal impairment. Requirements for glomerular filtration rate (GFR) determination prior to IV iodinated contrast administration are determined by local site standard practice. Criteria that should be considered include, but are not limited to, the following: * Age \>60 years old * History of renal disease, including dialysis, kidney transplant, single kidney, renal cancer, and renal surgery * History of hypertension requiring medical therapy * History of diabetes mellitus * Use of metformin or metformin-containing drug combinations * 4\. Women who are pregnant, breast feeding, or planning to become pregnant from screening until 30 days after the last administration of Omnipaque (iohexol). * 5\. Large breasted women that require multiple images per standard view of the breast (Tiling) as determined by their most recent mammogram.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE2
Enrollment 88
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Drug: Fisetin — Given PO
  • Drug: Placebo Administration — Given PO
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Change in 6-minute walk distance (6MWD) (Baseline to day 60)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-27
Completion: 2028-08-14
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI), National Institute on Aging (NIA)
Principal Investigators:
  • Mina S. Sedrak, MD (PRINCIPAL_INVESTIGATOR) - UCLA / Jonsson Comprehensive Cancer Center
Contact Information
Study Contact:
Mina S. Sedrak, MD
310-825-3181
msedrak@mednet.ucla.edu
Kelly Synold
424-440-3877
ksynold@mednet.ucla.edu
Mina S. Sedrak, MD
310-825-3181
msedrak@mednet.ucla.edu
UCLA Health Cancer Care in Alhambra
Interventions
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Drug: Fisetin — Given PO
  • Drug: Placebo Administration — Given PO
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (7 sites)
UCLA Health Cancer Care in Alhambra, Alhambra, California 91801 United States
UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California 90210 United States
UCLA Health Burbank Primary & Specialty Care, Burbank, California 91505 United States
City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States
UCLA Health Primary Care in Marina del Rey, Marina del Rey, California 90292 United States
UCLA Health Primary Care in Pasadena, Pasadena, California 91105 United States
Eligibility Criteria
Inclusion Criteria: * Women who are postmenopausal at the start of study treatment. Postmenopausal status will be established as follows: * Women aged: \>= 60 years OR * Women aged \< 60 years AND one of the following conditions is met: * They have not had any menstrual periods for at least 12 months in the absence of exogenous hormonal treatments, chemotherapy, and/or tamoxifen AND have serum estradiol and follicle-stimulating hormone (FSH) levels confirmed as being within the standard laboratory reference range for postmenopausal females. * They have documented irreversible bilateral oophorectomy. * They are receiving ovarian suppression with their breast cancer endocrine therapy * Women with a diagnosis of early-stage breast cancer (Stage I-III) treated with neo/adjuvant chemotherapy within 12 months of starting study treatment * No evidence of active/recurrent breast cancer or other serious chronic illnesses * Have evidence of frail health, defined as a diminished 6-minute walk distance (\< 400m) at baseline * Platelets \> 60,000/mm\^3 * White blood cell count \> 2,000/mm\^3 * Absolute neutrophil count \> 500/mm\^3 * Hemoglobin \>= 8.0 g/dL * Total bilirubin =\< 3.0 X upper limit of normal (ULN) * Aspartate aminotransferase (AST) =\< 4.0 x ULN * Alanine aminotransferase (ALT) =\< 4.0 x ULN * Estimated glomerular filtration rate (eGFR) of \>= 30mL/min/1.73m\^2 per the Modification of Diet in Renal Disease (MDRD) calculation * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Cancer-directed chemotherapy, biological therapy, or immunotherapy within 30 days prior to the start of study treatment. Exceptions include: trastuzumab, pertuzumab, pembrolizumab, tamoxifen, ribociclib, abemaciclib, aromatase inhibitors and/or ovarian suppression. * Surgery and/or radiation within the last 30 days of starting study treatment (Exception: invasive non- major procedures such as an outpatient biopsy) * Subjects taking medications that are considered prohibited. * Exception: Subjects taking any of the medications listed in under "Temporary medication adjustment required" may participate if they are otherwise eligible AND the medication can be safely withheld (from immediately before the 1st study agent administration until at least 10 hours after the last study agent administration, for each dosing interval) * On herbal and natural medications with possible senolytic properties (i.e., curcumin, kava kava, St. John's wort) and are unable or unwilling to hold its administration 2 days prior to and during study treatment dosing. Exceptions include cannabidiol (CBD), vitamins, probiotics, and fish oil. Other herbal and natural medications may be permitted or prohibited per clinician discretion * Subjects taking potentially senolytic agents within the last year: fisetin, quercetin, luteolin, dasatinib or imatinib (or other tyrosine kinase inhibitors), piperlongumine, or navitoclax * Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.) * Issues with tolerating oral medication (such as but not limited to, inability to swallow pills (g-tubes not allowed), malabsorption issues, ongoing nausea or vomiting during screening, history of Crohn's, gastric bypass/reduction, or celiac disease) * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion/fatigue, or cognitive function
Conditions Posttraumatic Stress Disorder, Major Dep...
Phase NA
Enrollment 960
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Royal Canadian Mounted Police (RCMP), like all public safety personnel (PSP), are frequently exposed to potentially psychologically traumatic events that contribute to posttraumatic stress injuries (PTSI). Addressing PTSI is impeded by the limited available research. The RCMP are working to build evidence-based solutions to PTSI and other mental health challenges facing their members, which by extension will help all PSP, as part of the Canadian Government Federal Framework on Posttraumatic Stress Disorder. A key element is the "Longitudinal Study of Operational Stress Injuries / Étude longitudinale sur les traumatismes liés au stress opérationnel", a study which has been renamed "Risk and Resiliency Factors in the RCMP: A Prospective Investigation", and is referred to as the "RCMP Study" for short. The RCMP Study has been detailed online (www.rcmpstudy.ca) and in a recently published peer-reviewed protocol paper, "The Royal Canadian Mounted Police (RCMP) Study: protocol for a prospective investigation of mental health risk and resilience factors" (https://doi.org/10.24095/hpcdp.42.8.02). The RCMP Study, part of the concerted efforts by the RCMP to reduce PTSI by improving access to evidence-based assessments, treatments, and training as well as participant recruitment and RCMP Study developments to date. The RCMP Study has been designed to (1) develop, deploy and assess the impact of a system for ongoing annual, monthly and daily evidence-based assessments; (2) evaluate associations between demographic variables and PTSI; (3) longitudinally assess individual differences associated with PTSI; (4) augment the RCMP Cadet Training Program with skills to proactively mitigate PTSI; and (5) assess the impact of the augmented training condition (ATC) versus the standard training condition (STC). Participants in the STC (n = 480) and ATC (n = 480) are assessed before and after training and annually for 5 years on their deployment date; they also complete brief monthly and daily surveys. The RCMP Study results are expected to benefit the mental health of all participants, RCMP and PSP by reducing PTSI among all who serve.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Emotional Resilience Skills Training (ERST) — The ERST training is designed as a "train the trainer" model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs.
  • Behavioral: Active Monitoring — Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.

Primary Outcomes

  • Change in Posttraumatic Stress Disorder Symptoms from Time 1 (pre-training; week 1) to Time 2 (post-training; week 26) (Time 1 (pre-training; week 1), Time 2 (post-training; week 26))
  • Sustained Posttraumatic Stress Disorder Symptoms from Time 2 (post-training; week 26) to Time 7 (5-year follow-up) (Time 2 (post-training; week 26), Time 3 (1-year follow-up), Time 4 (2-year follow-up), Time 5 (3-year follow-up), Time 6 (4-year follow-up), Time 7 (5-year follow-up))
  • Change in Major Depressive Disorder Symptoms from Time 1 (pre-training; week 1) to Time 2 (post-training; week 26) (Time 1 (pre-training; week 1), Time 2 (post-training; week 26))
  • Sustained Major Depressive Disorder Symptoms from Time 2 (post-training; week 26) to Time 7 (5-year follow-up) (Time 2 (post-training; week 26), Time 3 (1-year follow-up), Time 4 (2-year follow-up), Time 5 (3-year follow-up), Time 6 (4-year follow-up), Time 7 (5-year follow-up))
  • Change in Generalized Anxiety Disorder Symptoms from Time 1 (pre-training; week 1) to Time 2 (post-training; week 26) (Time 1 (pre-training; week 1), Time 2 (post-training; week 26))
  • Sustained Generalized Anxiety Disorder Symptoms from Time 2 (post-training; week 26) to Time 7 (5-year follow-up) (Time 2 (post-training; week 26), Time 3 (1-year follow-up), Time 4 (2-year follow-up), Time 5 (3-year follow-up), Time 6 (4-year follow-up), Time 7 (5-year follow-up))
  • Change in Panic Disorder Symptoms from Time 1 (pre-training; week 1) to Time 2 (post-training; week 26) (Time 1 (pre-training; week 1), Time 2 (post-training; week 26))
  • Sustained Panic Disorder Symptoms from Time 2 (post-training; week 26) to Time 7 (5-year follow-up) (Time 2 (post-training; week 26), Time 3 (1-year follow-up), Time 4 (2-year follow-up), Time 5 (3-year follow-up), Time 6 (4-year follow-up), Time 7 (5-year follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-04-22
Completion: 2029-12
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: true
Enrollment: 960 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Royal Canadian Mounted Police, Government of Canada, Ministry of Public Safety and Emergency Preparedness, Canadian Institute for Public Safety Research and Treatment
Principal Investigators:
  • R. Nicholas Carleton, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
R. Nicholas Carleton, PhD
306-337-2387
nick.carleton@uregina.ca
Jonathan Burry, PM
306-337-2667
Jonathan.Burry@uregina.ca
R. Nicholas Carleton, PhD
306-337-2387
nick.carleton@uregina.ca
University of Regina
Interventions
  • Behavioral: Emotional Resilience Skills Training (ERST) — The ERST training is designed as a "train the trainer" model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs.
  • Behavioral: Active Monitoring — Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
Study Locations (1 sites)
University of Regina, Regina, Saskatchewan S4S0A2 Canada
Eligibility Criteria
Inclusion Criteria: * Cadets starting the RCMP Cadet Training Program Exclusion Criteria: * Anyone other than cadets starting the RCMP Cadet Training Program
Conditions Breast Cancer, Quality of Life
Phase PHASE2
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine therapy alone after lumpectomy. The study population will include women age 65 years and older with low-risk tumor characteristics (tumor size \<2cm, grade 1-2, node-negative). APBI will consist of 5 fractions of radiation therapy delivered every other day to the lumpectomy cavity. Endocrine therapy will be chosen by the treating medical oncologist with an aim of 5 years duration, as tolerated by the patient. Quality of life outcomes will be measured at 1 year following lumpectomy and compared between groups. We hypothesize that the use of APBI may be superior in terms of quality of life when compared to endocrine therapy alone following lumpectomy while providing equivalent rates of disease control and overall survival. In this phase II study, we anticipate enrolling 90 women at N.C. Cancer Hospital in Chapel Hill, NC.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Accelerated Partial Breast Irradiation (APBI) — Radiation treatment delivered to the lumpectomy cavity.
  • Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene — Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.

Primary Outcomes

  • Patient reported outcomes assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 (1 year)
  • Patient reported outcomes assessed by EORTC QLQ-BR45 (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-05-17
Completion: 2032-04-15
Eligibility
Age: 65 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Principal Investigators:
  • Dana Casey, MD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Lori Stravers
+1 919-966-4432
lori_stravers@med.unc.edu
Jessica Buddenbaum
919-966-4432
jessica_buddenbaum@med.unc.edu
Dana Casey, MD
984-974-0400
dana_casey@med.unc.edu
University of North Carolina
Interventions
  • Radiation: Accelerated Partial Breast Irradiation (APBI) — Radiation treatment delivered to the lumpectomy cavity.
  • Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene — Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
Study Locations (1 sites)
University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: 1. Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. 2. Women greater than or equal to age 65 years with de novo invasive carcinoma of breast. 3. Pathological T1 (pT1) stage 4. Estrogen receptor (ER)/ Progesterone receptor (PR) positive (greater than or equal to 10% ER and PR by immunohistochemistry \[IHC\] staining) 5. Human epidermal growth factor receptor 2 (HER2) - according to American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines (0 or 1+ following IHC staining or proven negative by in-situ hybridization \[ISH\]) 6. Grade 1 or 2 overall tumor grade 7. Clinical or pathological N0 8. No lymphovascular space invasion (LVSI) 9. Final surgical margins ≥ 2 mm as per APBI criteria 10. Subjects with completed breast conserving surgery (BCS) with or without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). 11. Suitable for APBI as deemed by the treating radiation oncologist 12. Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. 13. Enrollment in another clinical trial is allowed if there would be no interference with interventions on this trial Exclusion Criteria: 1. Pre- or post-operative systemic chemotherapy while on this study. 2. Current ongoing treatment with anti-hormonal agents. If previously on anti-hormonal agents and planning to stop, the subject must discontinue within 30 days of randomization. 3. Hormonal replacement therapy (eligible if discontinued within 30 days of randomization). 4. Multifocal or multicentric tumor. 5. Receipt of tissue rearrangement in the lumpectomy cavity. 6. Synchronous bilateral breast cancer. 7. Clinical or imaging evidence of distant metastases. 8. Prior breast or thoracic radiation. 9. Autoimmune conditions with associated radiation risks. 10. Subjects with poor medical risk due to uncontrolled medical conditions that would deem them ineligible for hormonal or radiation therapy.
Conditions Gastric Cancer, Breast Cancer, Cervical ...
Phase PHASE1
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: KK-LC-1 TCR-T cells — Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
  • Drug: Aldesleukin — Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.

Primary Outcomes

  • Maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-09-26
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Christian Hinrichs
Collaborators: National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Principal Investigators:
  • Christian S Hinrichs, MD (PRINCIPAL_INVESTIGATOR) - Rutgers Cancer Institute
Contact Information
Study Contact:
Tobi Adewale
732-710-2406
olutobi@cinj.rutgers.edu
Tobi Adewale
732-710-2406
olutobi@cinj.rutgers.edu
Rutgers Cancer Institute
Tobi Adewale
732-710-2406
olutobi@cinj.rutgers.edu
RWJBarnabas Health - Robert Wood Johnson University Hospital
Interventions
  • Biological: KK-LC-1 TCR-T cells — Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
  • Drug: Aldesleukin — Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study Locations (2 sites)
Rutgers Cancer Institute, New Brunswick, New Jersey 08901 United States
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey 08901 United States
Eligibility Criteria
Inclusion Criteria: Subjects must meet all the following criteria to participate in this study. 1. Signed, written informed consent obtained prior to any study procedures. 2. Age ≥ 18 years at the time of informed consent. 3. Metastatic solid tumor with ≥ 10% of tumor cells positive for KK-LC-1 by IHC assay. Due to the low frequency of KK-LC-1 expression in most cancers, screening will focus on gastric, NSCLC, TNBC, and cervix cancers. The IHC test will be performed by the Rutgers Cancer Institute, Department of Biorepository Services. 4. HLA-A\*01:01 allele by HLA haplotype test. 5. Measurable disease per RECIST Criteria Version 1.1 at time of enrollment. 6. Prior treatment with cancer type-specific standard of care systemic cancer therapy is required. Standard treatment options must be considered and declined. Documentation of rationale is required if a subject is deemed unsuitable for standard therapy. 7. Subjects with ≤ 3 brain metastases that have been treated with surgery or stereotactic radiosurgery are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month before protocol treatment. Patients with surgically resected brain metastases are eligible. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening. 9. Negative pregnancy test for women under 55 and all women who have had a menstrual period in the last 12 months. A pregnancy test is not required for women who have had a bilateral oophorectomy or hysterectomy. 10. Men and women of child-bearing potential must agree to use adequate contraception (i.e., intrauterine device, hormonal/barrier method of birth control, abstinence, tubal ligation, or vasectomy) prior to study entry and for 12 months after treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. 11. Participants must have organ and marrow function as defined below: 1. Leukocytes \> 3,000/mcL 2. Absolute neutrophil count \> 1,500/mcL 3. Platelets \> 100,000/mcL 4. Hemoglobin \> 9.0 g/dL 5. Total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin \< 3.0 mg/dL. 6. Serum AST (SGOT)/ALT (SGPT) \< 2.5 x ULN 7. Calculated creatinine clearance (CrCl) \> 50 mL/min/1.73 m² for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation). 8. INR or aPTT ≤ 1.5 X ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must have a PT or PTT within therapeutic range and no history of severe hemorrhage. 12. Serology: * HIV antibody negative * Hepatitis B antigen negative * Hepatitis C antibody negative or HCV RNA negative (i.e., no current HCV infection) 13. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the KK-LC-1 TCR-T cells. Adverse events from prior therapy must have resolved to ≤ grade 1 according to CTCAE Version 5.0 or have demonstrated clinical stability and meet the eligibility criteria for the protocol. 14. Participants must agree to participate in Rutgers protocol 192103 (Pro2021002307) for gene therapy long term follow up and in Rutgers protocol 192002 (Pro2021000281) or NIH protocol 16C0061 (Rutgers 192202) for biospecimen collection study. Note: Patients may have undergone minor surgical procedures within the past three weeks, as long as all toxicities have recovered to Grade 1 or less. Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study: 1. Current treatment with another investigational agent. 2. History of severe allergic reactions to compounds of similar chemical or biologic composition to agents used in study. 3. History of coronary revascularization or ischemic symptoms unless patient has a normal cardiac stress test. 4. Documented LVEF of less than or equal to 45% tested. The following participants will undergo cardiac evaluations: 1. Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or 2. Age greater than or equal to 50 years old 5. Participants with baseline screening pulse oxygen level of less than or equal to 92% on room air will not be eligible. If the underlying cause of hypoxia improves, then they may be reevaluated. 6. Uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements. 7. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with KK-LC-1 TCR-T cells, breastfeeding should be discontinued if the mother is treated with KK-LC-1 TCR cells. The potential risks may also apply to other agents used in this study. 8. Participants with a systemic immunodeficiency including acquired deficiency such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency Disease are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune competence may be less responsive to the treatment. 9. Participants on immunosuppressive drugs including corticosteroids unless meeting criteria outlined in Section 6.1 (Prohibited Medications). 10. Subjects with HLA-A\*01:01 damaging mutation or allele loss or other molecular resistance detected by clinical or research genomic profiling will not be eligible. 11. Participants with potentially severe autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus are not eligible. Prior history of potentially severe autoimmune diseases without a current, active diagnosis is not exclusionary. Patients with less severe autoimmune diseases such as hypothyroidism, vitiligo, and other minor autoimmune disorders are eligible. 12. Participants with prior or concurrent malignancy whose natural history or treatment is unlikely to interfere with the safety or efficacy assessments of the investigational regimen are eligible for this trial. Examples include, but are not limited to: 1. Carcinoma in situ 2. Cutaneous skin cancers requiring only local excision 3. Low grade non-muscle invasive bladder cancer 4. Low grade prostate cancer Participants with prior or concurrent malignancy that do not meet the above criteria are excluded. 13. Subjects who received a live vaccine within 30 days prior to enrollment are not eligible. 14. Determination by the Principal Investigator that participation is not in the best interest of the research subject or may jeopardize the safety of the subject or integrity of the clinical trial data.
Conditions Radiotherapy, Breast Cancer
Phase PHASE3
Enrollment 1106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: No PMRT for mastectomy / No regional RT for BCS — * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
  • Radiation: PMRT for mastectomy / WBI + Regional RT for BCS — * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.

Primary Outcomes

  • Disease-Free Survival (7-Year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-08-01
Completion: 2033-12-31
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Principal Investigators:
  • Kyung Hwan Shin, MD. PhD. (PRINCIPAL_INVESTIGATOR) - Seoul National University Hospital
Contact Information
Study Contact:
Kyung Hwan Shin, MD. PhD.
+82-2-2072-2524
radiat@snu.ac.kr
Bum-Sup Jang, MD. PhD.
+82-2-2072-1161
bigwiz83@snu.ac.kr
Bum-Sup Jang, MD. PhD.
bigwiz83@snu.ac.kr
Seoul National University Hospital
Interventions
  • Radiation: No PMRT for mastectomy / No regional RT for BCS — * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
  • Radiation: PMRT for mastectomy / WBI + Regional RT for BCS — * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
Study Locations (1 sites)
Seoul National University Hospital, Seoul, Jongro-gu 03080 South Korea
Eligibility Criteria
Inclusion Criteria: * Patients aged 19 years or older. * A female patient who underwent breast-conserving surgery or mastectomy for invasive breast cancer. * Patient with stage pN1 after surgery on histopathologic examination. * However, if mastectomy was performed, 5 or more nodes should be resected in the case of 1 positive node, and axillary lymph node dissection (ALND) should be performed in case of 2 or 3 positive nodes. * Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive. * Patients who have received or are expected to undergo targeted therapy in the case of human epidermal growth factor receptor(HER)-2 positive. * Patients with Eastern Cooperative Oncology Group (ECOG) Scale 0-2. * Patients who agreed to participate in the study. Exclusion Criteria: * Patients who have received prior \[neoadjuvant\] chemotherapy. * Patients receiving radiation therapy for salvage or palliative purposes. * Patients with stage T4. * Patients with ipsilateral supraclavicular and internal mammary lymph node metastases or distant metastases. * Male breast cancer patient. * Patients who have previously received radiation therapy to the ipsilateral breast or supraclavicular region. * Patients having a history of cancer other than thyroid cancer, cervical carcinoma in situ, or skin cancer. * Patients diagnosed with ductal breast carcinoma in situ, lobular carcinoma in situ, phyllodes, metaplastic cancer, or benign tumors based on histological diagnosis.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camrelizumab — Intravenous (IV) infusion
  • Drug: Apatinib — po.
  • Drug: Nab-paclitaxel — IV infusion.
  • Drug: Epirubicin — IV infusion.
  • Drug: Cyclophosphamide — IV infusion.

Primary Outcomes

  • pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery (Up to approximately 28 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-11-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West China Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Principal Investigators:
  • Ting Luo, MD (PRINCIPAL_INVESTIGATOR) - West China Hospital
Contact Information
Study Contact:
Ting Luo, MD
+86 18602866299
tina621@163.com
Ting Luo, MD
+86 18602866299
tina621@163.com
West China Hospital, Sichuan University
Ting Tuo, MD
West China Hospital, Sichuan University
Interventions
  • Drug: Camrelizumab — Intravenous (IV) infusion
  • Drug: Apatinib — po.
  • Drug: Nab-paclitaxel — IV infusion.
  • Drug: Epirubicin — IV infusion.
  • Drug: Cyclophosphamide — IV infusion.
Study Locations (1 sites)
West China Hospital, Sichuan University, Chengdu, Sichuan 610041 China
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed breast cancer. * 18-75 Years, female. * Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage: II-III. * ECOG Performance Status of 0-1. * life expectancy is not less than 3 months. * at least one measurable lesion according to RECIST 1.1. * Adequate hematologic and organ function. * Must be willing to use an adequate method of contraception for the course of the study. Exclusion Criteria: * Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer. * Inflammatory breast cancer. * Has received prior any anti-tumor therapy within the past 12 months prior to signing informed consent, including chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TAE. * Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\], and/or anti-VEGFR agent. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Major surgical procedure within 4 weeks prior to initiation of study treatment. * Has a history of autoimmune disease. * Has a history of hypertension that not well controlled by antihypertensive treatment * Has a history of myocardial infarction, severe/unstable angina pectoris, NYHA Class 2 or above cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, or symptomatic congestive heart failure within the last 6 months. * Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases. * Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study. * Has a known history of Human Immunodeficiency Virus (HIV). * Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis. * Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia. * Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment. * Has evidence of active tuberculosis within 1 year prior to initiation of study treatment. * Prior allogeneic stem cell or solid organ transplantation. * Peripheral neuropathy grade ≥2. * Has clinically significant intestinal obstruction. * Arterial/venous thrombosis events that occurred within 3 months before enrollment, such as cerebrovascular accidents, deep vein thrombosis, or pulmonary embolism. * Has hemoptysis symptoms within 2 months before enrollment and the maximum daily hemoptysis ≥ 2.5 ml. * Clinically significant bleeding symptoms or clear bleeding tendency occurred within 3 months before enrollment. * Has known genetic or acquired bleeding or thrombotic tendency. * Abnormal coagulation (INR\>1.5 or APTT\>1.5 x ULN) with bleeding tendency, receiving thrombolysis or anticoagulation therapy, or requiring long-term antiplatelet therapy. * Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. * Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial. * History of neurological or psychiatric disorders, including epilepsy or dementia. * Any other situation evaluated by researchers.
Conditions Depression
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to answer a question on whether a Web App-based Lifestyle Physical Activity Promotion Program is effective in improving depressive symptom experience of midlife Korean American women (WPAPP-K).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Web-App based Lifestyle Physical Activity Promotion Program — WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences. The program includes 3 components in 2 languages (English and Korean): 1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers. 2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity. 3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.). Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls.
  • Behavioral: The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines — A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.

Primary Outcomes

  • Change in Center for Epidemiologic Studies Depression Scale-Korean (CESD-K) (Baseline(T0), 6-months post-intervention (T1), and post 12-months post-intervention (T2))
  • Change in Acculturation Stress Scale (ASS) (Baseline(T0), 6-months post-intervention (T1), and post 12-months post-intervention)
  • Change in Social Readjustment Rating Scale (SRRS) (Baseline(T0), 6-months post-intervention (T1), and post 12-months post-intervention)
  • Change in Personal Resource Questionnaire (PRQ-2000) (Baseline(T0), 6-months post-intervention (T1), and post 12-months post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-12
Completion: 2026-10
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Eun-Ok Im, PhD, MPH (PRINCIPAL_INVESTIGATOR) - The University of Texas at Austin
Contact Information
Study Contact:
Wonshik Chee, PhD
512-232-2121
wpapp.help@austin.utexas.edu
Wonshik Chee, PhD
512-232-2121
wpapp.help@austin.utexas.edu
The University of Texas at Austin
Interventions
  • Behavioral: Web-App based Lifestyle Physical Activity Promotion Program — WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences. The program includes 3 components in 2 languages (English and Korean): 1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers. 2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity. 3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.). Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls.
  • Behavioral: The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines — A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.
Study Locations (1 sites)
The University of Texas at Austin, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: * self-reported midlife Korean-American women * aged 40 to 60 years * whose parents and grandparents are of Korean descent; * who can read and write English or Korean; * who currently reside in the United States; * who are sedentary (without any disabilities preventing physical activity); * who are online through computers or mobile devices; * have experienced depressive symptoms during the past two weeks (1 to 10 on the Patient Health Questionnaire \[PHQ-9\],which is equivalent to the cut-point of minimal to moderate depression. Exclusion Criteria: * major signs or symptoms suggestive of pulmonary or CVD * history of a myocardial infarction, stroke, or Type I diabetes mellitus * blood pressure higher than 160/100 mm Hg * Use of beta-blockers, diltiazem, or verapamil

Mental Health in Primary Care

NCT05426057
Recruiting
Conditions Depression, Anxiety, Suicide, Drug Use
Phase NA
Enrollment 468
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate in an effectiveness-implementation type I hybrid trial, an enhanced version of eHealth Familias Unidas for reducing depressive, anxious symptoms and suicide behavior in Hispanic youth. The study will use a randomized rollout design with 18 pediatric primary care clinics in the South Florida area.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: eHealth Familias Unidas Mental Health — eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.

Primary Outcomes

  • Depression symptoms (Baseline to 3 months, baseline to 6 months, baseline to 18 months)
  • Anxiety symptoms (Baseline to 3 months, baseline to 6 months, baseline to 18 months)
  • Suicidality (Baseline to 3 months, baseline to 6 months, baseline to 18 months)
  • Change in drug use (Baseline to 3 months, baseline to 6 months, baseline to 18 months)
  • Center for Epidemiologic Studies Depression Scale (CESD) (Baseline to 3 months, baseline to 6 months, baseline to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-26
Completion: 2028-04-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 468 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Guillermo Prado, PhD (PRINCIPAL_INVESTIGATOR) - University of Miami
  • C. Hendricks Brown, PhD (PRINCIPAL_INVESTIGATOR) - Northwestern University
Contact Information
Study Contact:
Guillermo Prado, PhD
305-284-2002
gprado@miami.edu
Yannine Estrada, PhD
305-284-6191
yestrada@miami.edu
Luiza Mali, PhD
lvm852@med.miami.edu
Mailman for Child Devlopment
Interventions
  • Behavioral: eHealth Familias Unidas Mental Health — eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
Study Locations (17 sites)
Jessie Trice Community Health Center, Miami, Florida 33010 United States
Broward Community Health, Miami, Florida 33021 United States
Community Health of South Florida, Miami, Florida 33023 United States
Medlife Clinical Research, Miami, Florida 33125 United States
Prime Care Health, Miami, Florida 33134 United States
Care Resource, Miami, Florida 33135 United States
Mailman for Child Devlopment, Miami, Florida 33136 United States
Pediatric Mobile Clinic, Miami, Florida 33136 United States
UM Pediatric Mobile Clinic, Miami, Florida 33136 United States
UM UHealth Pediatrics at the Professional Arts Center, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: 1. Female and male adolescents, who self-identify as Hispanic (or Latino(a)) 2. Adolescent between the ages of 12 - 16 years 3. Adolescent living with an adult primary caregiver who is willing to participate 4. Families must have broadband internet access on a device, including (but not limited to) a smartphone, iPad, tablet, computer at their home or other location (e.g., school, library, etc.) 5. Families screening positive on poor family communication (a score of less than 75 on the communication measure; see measures) or youth reporting elevated depressive or anxiety symptom scores (defined as 70 to 90 on the K-CAT) or a history of suicide behavior (ideation or attempts). Exclusion Criteria: * Families reporting plans to move out of the South Florida area during the study period.
Conditions Type 1 Diabetes, Type 2 Diabetes, Cystic...
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Point of Care Autonomous AI diabetic retinopathy exam — Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.

Primary Outcomes

  • Proportion screened for diabetic retinopathy (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-11
Completion: 2026-12-30
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Principal Investigators:
  • Risa M Wolf, MD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Risa M Wolf, MD
4109556463
RWolf@jhu.edu
Alvin Liu, MD
tliu25@jhmi.edu
Risa M Wolf, MD
410-955-6463
rwolf@jhu.edu
Johns Hopkins Pediatric Diabetes Center
Interventions
  • Diagnostic Test: Point of Care Autonomous AI diabetic retinopathy exam — Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
Study Locations (1 sites)
Johns Hopkins Pediatric Diabetes Center, Baltimore, Maryland 21287 United States
Eligibility Criteria
Inclusion Criteria: Meets American Diabetes Association (ADA) criteria for diabetic retinopathy screening: * Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty * Diagnosis of Type 2 diabetes Enriched cohort: * Patients with Type 1 or Type 2 diabetes, * 8-21 years of age with known diabetic retinopathy (true positives). * No time limit on last diabetic eye exam. Exclusion Criteria: * Known diabetic eye exam in the last 12 months